

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

1 to 6. (canceled)

7. (currently amended) A method of ~~preventing or~~ treating cancer, comprising the co-administration of interleukin 18 and a recombinant herpes simplex virus that selectively replicates in cancer cells.

8. (canceled)

9. (currently amended) The method according to claim 7 8, wherein the interleukin 18 is administered systemically.

10. (currently amended) The method according to claim 9, further comprising local administration of ~~wherein interleukin 12 is additionally administered locally~~ at a tumor tissue.

11. (currently amended) The method according to claim 10 9, wherein a gene coding for interleukin 12 has been inserted expressibly in the genomic DNA of the recombinant herpes simplex virus.

12. (currently amended) The method according to any of claims 7 or 9 to 11, wherein the γ 34.5 gene and ICP6 gene of the recombinant herpes simplex virus have been deleted or inactivated.

13. (previously presented) The method according to claim 12, wherein the ICP47 gene of the recombinant herpes simplex virus has also been deleted or inactivated.

14. (currently amended) The method according to any of claims 7 or 9 to 13, wherein the method of ~~preventing or~~ treating cancer is a method of ~~preventing or~~ treating cancer at a location outside the tumor tissue inoculated with the recombinant herpes simplex virus.

15. (currently amended) A method of treating cancer comprising ~~An agent for treating or preventing cancer, wherein the agent contains~~ injecting a recombinant herpes simplex virus that selectively replicates in cancer cells into a tumor tissue and administering systemically interleukin 18, the agent is administered by injection within a tumor tissue in combination with the systemic administration of interleukin 18, and wherein the γ 34.5 gene and ICP6 gene of the recombinant herpes simplex virus have been deleted or inactivated and a gene coding for interleukin 12 has been inserted as an expressible construct in the

genomic DNA of the recombinant herpes simplex virus.

16. (currently amended) The method of treating cancer agent according to claim 15 ~~for treating or preventing cancer~~, wherein the ICP47 gene of the recombinant herpes simplex virus has also been deleted or inactivated.